Abstract
Estimates of the frequency of GH deficiency range from 1:4,000 to 1:10,000. Most cases are sporadic and presumed to be secondary to a wide variety of aetiologies. However, in families with consanguinity, or when a second case occurs in the same family, a genetic cause may be suspected. Given that the patient is isolated GH deficient four distinct familial types of isolated GH deficiencies (IGHD) are well-differentiated on the basis of inheritance, hormonal deficiencies as well as molecular analyses. Two forms are autosomal recessively (IGHD type IA and IB), one is autosomal dominantly (IGHD type II) and one X-linked inherited. In this review, we focus on the secretory pathway of peptide hormones in general and on the possible mechanisms causing IGHD type II in detail. Most interestingly, in IGHD type II the apparently same phenotype of IGHD is caused by distinct GH-1 gene alterations leading to different blockades within the secretory pathway. Furthermore, this type of IGHD, in addition to some other specific GH-1 gene mutations, provides the most important opportunity to shed light on cell-biological mechanisms far beyond its pure description at the DNA/RNA level.
References
1.
Phillips JA III: Inherited defects in growth hormone synthesis and action; in Scriver Ch, Beaudet AL, Sly WS, Valle D (eds): The Metabolic Basis of Inherited Disease, ed 7. New York, McGraw-Hill, 1995, pp 3023-3044.
2.
Vimpani GV, Vimpani AF, Lidgard GP, Cameron EHD, Farquhar JW: Prevalence of severe growth hormone deficiency. Br Med J 1977;ii:427–430.
3.
Lacey KA, Parkin JM: Causes of short stature: A community study of children in Newcastle upon Tyne. Lancet 1974;i:42–45.
4.
Rona RJ, Tanner JM: Aetiology of idiopathic growth hormone deficiency in England and Wales. Arch Dis Child 1977;52:197–208.
5.
Lindsay R, Feldkamp M, Harris D, Robertson J, Rallison M: Utah growth study: Growth standards and the prevalence of growth hormone deficiency. J Pediatr 1994;125:29–35.
6.
Wagner JK, Eblé A, Hindmarsh PC, Mullis PE: Prevalence of human GH-1 gene alterations in patients with isolated growth hormone deficiency. Pediatr Res 1996;43:105–110.
7.
Illig R: Growth hormone antibodies in patients treated with different preparations of human growth hormone (hGH). J Clin Endocrinol Metab 1970;31:679–688.
8.
Laron Z, Kelijman M, Pertzelan A, Keret R, Shoffner IM, Parks JS: Human growth hormone deletion without antibody formation or growth arrest during treatment: A new disease entity? Isr J Med Sci 1985;250:999–1006.
9.
Mullis PE, Akinci A, Kanaka Ch, Eblé A, Brook CGD: Prevalence of human growth hormone-1 gene deletions among patients with isolated growth hormone deficiency from different populations. Pediatr Res 1992;31:532–534.
10.
Kamijo T, Phillips III JA, Ogawa M: Screening for growth hormone gene deletions in patients with isolated growth hormone deficiency. J Pediatr 1991;118:245–248.
11.
Vnencak-Jones CL, Phillips III JA: Hot spots for growth hormone gene deletions in homologous regions outside Alu repeats. Science 1990;250:1745–1748.
12.
Kuhlmann BV, Mullis PE: Genetics of the growth hormone axis. J Pediatr Endocrinol Metab 1997;10:161–174.
13.
Fleisher TA, White RM, Broder S, Nissley SP, Blaese RM, Mulvihill H, Olive G, Waldmann TA: X-linked hypogammaglobulinemia and isolated growth hormone deficiency. N Engl J Med 1980;302:1429–1439.
14.
Sitz KV, Burks W, Williams LW, Kemp SF, Steele RW: Confirmation of X-linked hypogammaglobulinemia with isolated growth hormone deficiency as a disease entity. J Pediatr 1990;116:292–294.
15.
Cogan JD, Phillips III JA, Schenkman SS, Milner RDG, Sakati N: Familial growth hormone deficiency: A model of dominant and recessive mutations affecting a monomeric protein. J Clin Endocrinol Metab 1994;79:1261–1265.
16.
Duquesnoy P, Simon D, Netchine I, Dastot F, Sobrier ML, Goossens M, Cernicchow P, Amselem S: Familial isolated growth hormone deficiency with slight height reduction due to a heterozygote mutation in GH gene. 80th Annu Meeting Endocr Soc 1998; abstr P2–202.
17.
Moseley CT, Mullis PE, Prince MA, Phillips JA 3rd: An exon splice enhancer mutation causes autosomal dominant GH deficiency. J Clin Endocrinol Metab 2002;87:847–852.
18.
Wajnrajch MP, Gertner JM, Mullis PE, Deladoëy J, Cogan JD, Lekhakula S, Kim S, Dannies PS, Saenger P, Moshang T, Phillips JA III, Leibel RL: Arg183His, a new mutational ‘hot-spot’ in the growth hormone (GH) gene causing isolated GH deficiency type II. J Endocr Genet 2000;1:125–135.
19.
Dannies PS: Protein hormone storage in secretory granules: Mechanisms for concentration and sorting. Endocr Rev 1999;20:3–21.
20.
Dannies PS: Protein folding and deficiencies caused by dominant-negative mutants of hormones. Vitam Horm 2000;58:1–26.
21.
Dannies PS: Concentrating hormones into secretory granules: Layers of control. Mol Cell Endocrinol 2001;177:87–93.
22.
Arnold A, Horst SA, Gardella TJ, Baba H, Levine MA, Kronenberg HM: Mutation of the signal peptide-encoding region of the preproparathyroid hormone gene in familial isolated hypoparathyroidism. J Clin Invest 1990;86:1084–1087.
23.
Ito M, Jameson JL, Ito M: Molecular basis of autosomal dominant neurohypophyseal diabetes insipidus: Cellular toxicity caused by the accumulation of mutant vasopressin precursors within the endoplasmatic reticulum. J Clin Invest 1997;99:1897–1905.
24.
Kuznetsov G, Nigam SK: Folding of secretory and membrane proteins. N Engl J Med 1998;339:1688–1695.
25.
Sferra TJ, Collins FS: The molecular biology of cystic fibrosis. Annu Rev Med 1993;44:133–144.
26.
Lomas DA, Evans DL, Finch JT, Carrell RW: The mechanism of Z a1-antitrypsin accumulation in the liver. Nature 1992;357:605–607.
27.
Chessler SD, Byers PH: BiP binds type I procollagen pro a chain with mutations in the carboxy-terminal propeptide synthesized by cells from patients with osteogenesis imperfecta. J Biol Chem 1993;268:18226–18233.
28.
Hurtley SM, Helenius A: Protein oligomerization in the endoplasmic reticulum. Annu Rev Cell Biol 1989;5:277–307.
29.
Ellgard L, Molinari M, Helenius A: Setting the standards: Quality control in the secretory pathway. Science 1999;286:1882–1888.
30.
Wickner S, Maurizi MR, Gottesman S: Posttranslational quality control: Folding, refolding and degrading proteins. Science 1999;286:1888–1893.
31.
Arnold J, Dawson S, Fergusson J, Lowe J, Landon M, Mayer RJ: Ubiquitin and its role in neurodegeneration. Progr Brain Res 1998;117:23–34.
32.
Thomas PJ, Qu BH, Pedersen PL: Defective protein folding as a basis of human disease. TIBS 1995;20:456–459.
33.
Ciechanover A: The ubiquitin-proteasome proteolytic pathway. Cell 1994;79:13–21.
34.
Schwartz AL, Ciechanover A: The ubiquitin-proteasome pathway and pathogenesis of human diseases. Annu Rev Med 1999;50:57–74.
35.
Werner ED, Brodsky JL, McCraken AA: Proteasome-dependent endoplasmatic reticulum-associated protein degradation: An unconventional route to a familiar fate. Proc Natl Acad Sci USA 1996;93:13797–13801.
36.
Sommer T, Wolf DH: Endoplasmatic reticulum degradation: Reverse protein flow of no return. FASEB J 1997;11:1227–1233.
37.
Kim PS, Arvan P: Endocrinopathies in the family of endoplasmatic reticulum (ER) storage diseases: Disorders of protein trafficking and the role of ER molecular chaperones. Endocr Rev 1998;19:173–202.
38.
Presley JF, Cole NB, Schroer TA, Hirschberg K, Zaal KJ, Lippingcott-Schwartz J: ER-to-Golgi transport visualized in living cells. Nature1997;389:81–85.
39.
Presley JF, Smith C, Hirschberg K, Miller C, Cole NB, Zall KJM, Lippincott-Schwartz J: Golgi membrane dynamics: Video essay. Mol Biol Cell 1998;9:1617–1626.
40.
Arvan P, Castle D: Sorting and storage during granule biosynthesis: Looking backward and looking forward. Biochem J 1998;332:593–610.
41.
Molinete M, Irminger JC, Tooze SA, Halban PA: Trafficking/sorting and granule biogenesis in the beta-cell. Semin Cell Dev Biol 2000;11:243–251.
42.
Rambourg A, Clermont Y, Chretien M, Olivier L: Formation of secretory granules in the Golgi apparatus of prolactin cells in the rat pituitary gland: A stereoscopic study. Anat Rec 1992;232:169–179.
43.
Arrandale JM, Dannies PS: Inhibition of rat prolactin (PRL) storage by coexpression of human PRL. Mol Endocrinol 1994;8:1083–1090.
44.
de Vos AM, Ultsch M, Kossiakoff AA: Human growth hormone and extracellular domain of its receptor: Crystal structure of the complex. Science 1992;255:306–312.
45.
Cunningham BC, Ultsch M, de Vos AM, Mulkerrin MG, Clauser KR, Wells JA: Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. Science 1991;254:821–825.
46.
Binder G, Brown M, Parks JS: Mechanisms responsible for dominant expression of human growth hormone mutations. J Clin Endocrinol Metab 1996;81:4047–4050.
47.
Lee MS, Wajnrajch MP, Kin SS, Plotnick LP, Gertner JM, Leibel RL, Dannies PS: Autosomal dominant growth hormone deficiency type II: The des32–71-growth hormone deletion mutant suppresses secretion of the wild-type growth hormone. Endocrinology 2000;141:883–890.
48.
Deladoëy J, Stocker P, Mullis PE: Autosomal dominant GH deficiency due to an Arg183His GH-1 gene mutation: Clinical and molecular evidence of impaired regulated GH secretion. J Clin Endocrinol Metab 2001;86:3941–3947.
49.
Graves TK, Patel S, Dannies PS, Hinkle PM: Misfolded growth hormone causes fragmentation of the Golgi apparatus and disrupts endoplasmic reticulum-to-Golgi traffic. J Cell Sci 2001;114:3685–3694.
50.
Sun Z, Lee MS, Rhee HK, Arrandale JM, Dannies PS: Inefficient secretion of human H27A-prolactin, a mutant that does not bind Zn2+. Mol Endocrinol 1997;11:1544–1551.
51.
Procter AM, Phillips JA 3rd, Cooper DN: The molecular genetics of growth hormone deficiency. Hum Genet 1998;103:255–272.
52.
Hayashi Y, Kamijo T, Yamamoto M, Ohmori S, Phillips JA 3rd, Ogawa M, Igarashi Y, Seo H: A novel mutation at the donor splice site of intron 3 of the GH-I gene in a patient with isolated growth hormone deficiency. Growth Horm IGF Res 1999;9:434–437.
53.
Kamijo T, Hayashi Y, Shimatsu A, Kinoshita E, Yoshimoto M, Ogawa M, Seo H: Mutations in intron 3 of GH-1 gene associated with isolated GH deficiency type II in three Japanese families. Clin Endocrinol (Oxf) 1999;51:355–360.
54.
Cogan JD, Ramel B, Lehto M, Phillips JAIII, Prince MA, Blizzard RM, deRavel TJL, Brammert M, Groop L: A recurring dominant-negative mutation causes autosomal dominant growth hormone deficiency: A clinical research center study. J Clin Endocrinol Metab 1995;80:3591–3595.
55.
Missarelli C, Herrera L, Mericq V, Carvallo P: Two different 5′ splice site mutations in the growth hormone gene causing autosomal dominant growth hormone deficiency. Hum Genet 1997;101:113–117.
56.
Binder G, Ranke MB: Screening for growth hormone (GH) gene splice-site mutations in sporadic cases with severe isolated GH deficiency using ectopic transcript analysis. J Clin Endocrinol Metab 1995;80:1247–1252.
57.
Phillips JA3rd, Cogan JD: Genetic basis of endocrine disease. 6. Molecular basis of familial human growth hormone deficiency. J Clin Endocrinol Metab 1994;78:11–16.
58.
Cogan JD, Prince MA, Lekhakula S, Bundey S, Futrakul A, McCarthy AMS, Phillips JA 3rd: A novel mechanism of aberrant pre-mRNA splicing in humans. Hum Mol Genet 1997;6:909–912.
59.
McCarthy EM, Phillips JA 3rd: Characterization of an intron splice enhancer that regulates alternative splicing of human GH pre-mRNA. Hum Mol Genet 1998;7:1491–1496.
60.
Igarashi Y, Ogawa M, Kamijo T, Iwatani N, Nishi Y, Kohno H, Masumura T, Koga J: A new mutation causing inherited growth hormone deficiency: A compound heterozygote of a 6.7 kb deletion and a two base deletion in the third exon of the GH-1 gene. Hum Mol Genet 1993;2:1073–1074.
61.
Lykke-Andersen J, Shu MD, Steitz JA: Human Upf proteins target an mRNA for nonsense-mediated decay when bound downstream of a termination codon. Cell 2000;103:1121.
62.
Muhlrad D, Parker R: Aberrant mRNAs with extended 3′ UTRs are substrates for rapid degradation by mRNA surveillance. RNA 1999;5:1299–1307.
63.
Lee MS, Zhu YL, Chang JE, Dannies PS: Acquisition of Lubrol insolubility, a common step for growth hormone and prolactin in the secretory pathway of neuroendocrine cells. J Biol Chem 2001;276:715–721.
64.
Cunningham BC, Mulkerrin MG, Wells JA: Dimerization of human growth hormone by zinc. Science 1991;253:545–548.
65.
Hayashi Y, Yamamoto M, Ohmori S, Kamijo T, Ogawa M, Seo H: Inhibition of growth hormone (GH) secretion by a mutant GH-I gene product in neuroendocrine cells containing secretory granules: An implication for isolated GH deficiency inherited in an autosomal dominant manner. J Clin Endocrinol Metab 1999;84:2134–2139.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
